slides · global inventory
Chart
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 78,138
Current window 56,611-56,640
Pages 2,605
Rows per page 30
Component
56,611-56,640 of 78,138
05
The chart highlights the company's ability to grow both organically and through acquisitions.Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations 1 hit
12
The chart shows a clear downward trend in expense ratios from 73% for new members (<6 months) to 40% for long-term members (>36 months).Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
The slide uses a split-layout with company context on the left and a metrics dashboard on the right.Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations 1 hit
31
The chart is a classic waterfall diagram illustrating the financial flow of a capitated contract.Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations 1 hit
32
The chart uses a standard waterfall structure to decompose revenue into costs and profit.Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations 1 hit
35
Cano Health | Investor Presentation Deck | 45 slidesCano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations 1 hit
36
Cano Health | Investor Presentation Deck | 45 slidesCano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations 1 hit
37
The chart compares medical claims expense ratios for members with <24 months vs >24 months tenure, showing a consistent improvement (lower ratio) for longer-tenured members.Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations 1 hit
38
The chart demonstrates that while expense ratios increase with the number of chronic conditions, they remain within a specific range for the company's model.Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations 1 hit
39
Data represents 2019 South Florida at-risk Medicare membership.Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations 1 hit
40
The chart highlights the shift to telehealth during the peak of the pandemic while maintaining total visit volume.Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations 1 hit
43
Includes a timeline of market entry and expansion activities.Cano Health | Investor Presentation Deck | 45 slides · Cano Health
Pitch deck Investor relations 1 hit
10
The chart uses a conceptual line graph to show the impact of two specific genetic modifications on the duration of CAR-T cell activity.Caribou Biosciences | IPO Presentation Deck | 44 slides · Caribou Biosciences
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
15
The charts show that chRDNA guides maintain high on-target editing while significantly reducing off-target editing compared to all-RNA guides.Caribou Biosciences | IPO Presentation Deck | 44 slides · Caribou Biosciences
Pitch deck Investment bank Beat · TractionLoop · Zoom In1 hit
17
The chart is a flow cytometry plot showing insertion efficiency across two inserts.Caribou Biosciences | IPO Presentation Deck | 44 slides · Caribou Biosciences
Pitch deck Investment bank Beat · TractionLoop · Zoom In1 hit
18
The slide uses a before/after diagram to explain the biological problem of translocation and a comparative box to show the performance improvement.Caribou Biosciences | IPO Presentation Deck | 44 slides · Caribou Biosciences
Pitch deck Investment bank Beat · TractionLoop · Zoom In1 hit
22
Includes bioluminescence imaging time-series and Kaplan-Meier survival curve.Caribou Biosciences | IPO Presentation Deck | 44 slides · Caribou Biosciences
Pitch deck Investment bank Beat · Traction1 hit
23
Kaplan-Meier survival plots are standard for preclinical efficacy demonstration.Caribou Biosciences | IPO Presentation Deck | 44 slides · Caribou Biosciences
Pitch deck Investment bank Beat · Traction1 hit
30
The chart shows in vitro cytotoxicity measured 24 hours after co-incubation at various effector-to-target ratios.Caribou Biosciences | IPO Presentation Deck | 44 slides · Caribou Biosciences
Pitch deck Investment bank Beat · Traction1 hit
35
The chart is a Kaplan-Meier survival plot. The p-value < 0.0001 indicates statistical significance.Caribou Biosciences | IPO Presentation Deck | 44 slides · Caribou Biosciences
Pitch deck Investment bank Beat · Traction1 hit
08
Central Pacific Financial | Results Presentation Deck | 13 slidesCentral Pacific Financial | Results Presentation Deck | 13 slides · Central Pacific Financial
Conference presentation Investor relations Beat · Desire1 hit
09
The pie chart visualizes the breakdown of the $5,077MM total loan portfolio.Central Pacific Financial | Results Presentation Deck | 13 slides · Central Pacific Financial
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
12
The slide uses a grouped bar chart to show digital penetration across four regions over three years.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations 1 hit
13
The slide uses a grouped bar chart format to show year-over-year and two-year growth rates for four key financial metrics.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations 1 hit
18
The slide uses a color-coded system where green represents digital channels.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations 1 hit
07
The chart uses a waterfall structure to show the cumulative total of patient lives affected across different cancer types and regions.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · ProblemLoop · Pattern Hunter1 hit
15
The chart shows a logarithmic scale for IC50 (nM) across different cell lines grouped by mutation status (BRAF, HRAS, KRAS, NRAS, wildtype).Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
18
The slide uses a comparative experimental design to demonstrate the superior efficacy of ERAS-007 in a specific biological pathway.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
22
The chart displays individual patient responses (waterfall plot) categorized by dose level.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Traction1 hit
23
The chart uses color to represent dosage and symbols to represent clinical response (Partial Response, Stable Disease, Progressive Disease).Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Traction1 hit